Loading…
Results from a recent pharmacokinetic simulation analysis were announced.
Tharimmune, Inc. announced results from a recent pharmacokinetic simulation analysis of its lead clinical asset, TH104, a buccal film formulation of nalmefene. The analysis provided insights into the drug's absorption, distribution, metabolism, and excretion properties.
The company shared that the simulation results support the continued development of TH104, highlighting its potential as a treatment option. Tharimmune plans to use these findings to inform future clinical trials and regulatory submissions.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.